CD274 and non-small cell lung carcinoma: By these limitations, we can conclude that oncologists should remember that the bioselection of NSCLC patients by the PD-L1 staining has still some technical and interpretative caveat. On the other hand, after several efforts in order to harmonize the read-out lecture of PD-L1 status among different antibody clones, assays, and platforms, pathologists have now focused experiences and adequate training to give more detailed and reproducible PD-L1 results to clinicians [20, 21].